26 May 2020
MU researchers examine impact of menopause on cognitive function
Columbia, MO, USA – Characterized by a buildup of amyloid plaques in the brain, Alzheimer’s is an irreversible disease that leads to memory loss and a decrease in cognitive function. More than 5 million Americans suffer with the brain condition, which is the sixth leading cause of death in the United States. While the causes of Alzheimer’s are not fully understood, scientists believe genetic, lifestyle and environmental factors are involved in the disease’s development.
Now, researchers at the University of Missouri have found that the decline of reproductive hormones due to ovary removal, which is a model of menopause, can reduce cognitive function and potentially play a role in the development of Alzheimer’s disease in women. The findings could help explain why women make up nearly two-thirds of people in the United States with Alzheimer’s disease, although gender is just one of many contributing factors. The study is published in the Journal of Alzheimer's Disease.
Yuksel and Cansu Agca, researchers at the MU College of Veterinary Medicine, Mutant Mouse Resource and Research Center and Comparative Medicine Program, used rats experiencing surgically induced menopause to serve as Alzheimer’s models at Discovery Ridge Research Park. After placing the rats in a special maze designed to test their behavior, they found that the rats with induced menopause displayed poor memory and learning, indicating a decline in cognitive function.
“We wanted to see what impact various interventions, such as hormone depletion from menopause, had on the potential development of Alzheimer’s,” said Yuksel Agca, associate professor of veterinary pathology. “These animal models can be useful for future testing to examine the impact of a variety of other factors, such as alcohol, smoking, diet, exercise, hypertension or previous traumatic brain injuries.”
Although there is no cure for Alzheimer’s currently, studying how the age-related disease progresses over time in animals can help better inform the development of therapeutic drugs for humans, such as hormone replacement therapy. Lifestyle choices can also be made to decrease the risk of developing Alzheimer’s disease.
“While some people are genetically predisposed, or more likely, to develop Alzheimer’s, avoiding bad habits like an unhealthy diet or lack of exercise can help reduce the risks,” lead author Cansu Agca said. “It’s a complicated disease to understand because we all have variations in our genes, and we each respond to lifestyle choices and environmental factors differently, but this research can help us learn which factors are potentially contributing to or increasing the risk of Alzheimer’s.”
The research is an example of translational medicine, a major component of the NextGen Precision Health Institute. By partnering with government and industry leaders, the institute will empower interdisciplinary collaborations and life-changing precision health advancements targeting individual genetic, environmental and lifestyle factors.
NOTES FOR EDITORS:
Full study: “Ovariectomy Influences Cognition and Markers of Alzheimer's Disease” by C Agca, D Klakotskaia, EG Stopa,† TR Schachtman, and Y Agca (DOI 10.3233/JAD-190935), published in Journal of Alzheimer’s Disease, Vol. 73, Iss.2 (Jan 2020). The article is available at: content.iospress.com/articles/journal-of-alzheimers-disease/jad190935.
The research was supported by a University of Missouri-Research Incentive Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
About the Journal of Alzheimer's Disease
Now in its 23rd year of publication, the Journal of Alzheimer's Disease (JAD) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. JAD has a Journal Impact Factor of 3.517 according to Journal Citation Reports (Web of Science Group, 2019) and is published by IOS Press. j-alz.com